Overall Survival Subgroup Analyses for Prior Taxane Use in the Phase 3 ROSELLA Trial of Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer
Friday, May 29, 2026 1 min read
Key Takeaway: The Phase 3 ROSELLA trial results were presented at the American Society of Clinical Oncology Annual Meeting, highlighting the overall survival subgroup analyses for patients with platinum-resistant ovarian cancer. The study compares the efficacy of relacorilant plus nab-paclitaxel against nab-paclitaxel monotherapy, focusing on patients with prior taxane use. The findings suggest potential benefits of the combination therapy.
Price reaction · baseline $69.49 (2026-05-29 close) · hit after-hours · 2 other CORT headline(s) in the window, move may be shared
day 0 close · peak
+1.4%
Market Sentiment Analysis
POSITIVE FACTORS
The study presents promising results for relacorilant in combination with nab-paclitaxel.
The trial focuses on a specific patient subgroup, enhancing treatment personalization.
Presentation at a major conference indicates recognition and interest in the findings.
Full Press Release Details
Presented : American Society of Clinical Oncology Annual Meeting , 29 May 2026, Chicago, IL
Presenter : Lucy Gilbert, MD , MSc , FRCOG
Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.
Download Presentation
The post Overall Survival Subgroup Analyses for Prior Taxane Use in the Phase 3 ROSELLA Trial of Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer appeared first on Corcept Therapeutics .
Frequently Asked Questions
What was the focus of the ROSELLA trial?
The ROSELLA trial focused on the efficacy of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.
Where were the trial results presented?
The trial results were presented at the American Society of Clinical Oncology Annual Meeting in Chicago.
Who presented the ROSELLA trial findings?
The findings were presented by Lucy Gilbert, MD, MSc, FRCOG.
What does the trial compare?
The trial compares relacorilant plus nab-paclitaxel against nab-paclitaxel monotherapy.